Derbend Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Derbend Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$250K	Sell	3,673 -80	-2%	-$5.73K	0.12%	102
2023 Q4	$235K	Buy	+3,753	New	+$207K	0.14%	95
2023 Q3	–	Sell	-4,175	Closed	-$234K	–	98
2023 Q2	$234K	Buy	+4,175	New	+$237K	0.16%	70
2022 Q4	–	Sell	-4,585	Closed	-$300K	–	78
2022 Q3	$300K	Sell	4,585 -82	-2%	-$5.94K	0.24%	59
2022 Q2	$284K	Sell	4,667 -7,047	-60%	-$414K	0.24%	56
2022 Q1	$888K	Hold	11,714	–	–	0.87%	39
2021 Q4	$888K	Sell	11,714 -2,249	-16%	-$196K	0.87%	39
2021 Q3	$1.56M	Buy	13,963 +1,465	+12%	+$184K	1.47%	18
2021 Q2	$2.02M	Buy	+12,498	New	+$1.52M	1.88%	15

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Derbend Asset Management's CRSP Position: Q1 2024 in Review

Derbend Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 2.1% in Q1 2024, selling an estimated $5.73K and leaving 3,673 shares worth $250K. The position accounts for 0.12% of the portfolio, ranked #102.

Derbend Asset Management first reported a position in CRSP in Q2 2021 and has held it in 9 quarters since. The position peaked at $2.02M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Derbend Asset Management held 3,673 shares of CRISPR Therapeutics worth $250K as of Q1 2024.
Derbend Asset Management sold 80 CRISPR Therapeutics shares in Q1 2024, an estimated $5.73K.
CRISPR Therapeutics made up 0.12% of Derbend Asset Management's portfolio in Q1 2024, its #102 holding.
Derbend Asset Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 9 quarters since.
Derbend Asset Management's CRISPR Therapeutics position peaked at $2.02M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Derbend Asset Management's 13F filing for Q1 2024, filed 30 Apr 2024.